Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia

Coronavirus Disease 2019 (COVID-19) Pneumonia Clinical Trial

Official title:

A 8-Week Trial of Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04713878
• Other study ID #: 2020.05.20
• Status: Completed
• Phase: N/A
• Start date: May 8, 2020
• Est. completion date: July 15, 2020

Study information

• Verified date: January 2021
• Source: Kanuni Sultan Suleyman Training and Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Due to the cytokine storm that develops as a result of Coronavirus Disease 2019 (COVID-19) infection, some patients hospitalization to intensive care cause of pneumonia, Acute Respiratory Distress Syndrome (ARDS) and multiple organ failure. Mortality is higher in treatment-resistant cases. Purpose of this study: 1. Providing immune modulation by Stem Cell Transplantation and reducing the damage caused by cytokine storm to tissues and organs, 2. Correcting immunosuppression and fight against COVID-19 virus by editing B and T cells, 3. It is to accelerate healing in organ damage by increasing growth factors through mesenchymal stem cells. Primary outcome: Improvement of clinical symptoms, reduction of cytokine storm Secondary outcome: Recovery of patients; from mechanical ventilation

Description:

Study design and participants This study was a single-center open-label, randomized trial conducted at an Education and Training Hospital, Istanbul from May to July, 2020, and it was performed according to the Declaration of Helsinki and approved by the Ethics Committee and health ministry (No:2020.05.20). Written informed consent was obtained from all patients or their representatives when data were collected prospectively. Age, gender, mortality status, APACHE II score, number of days in ICU, procalcitonin and C-reactive protein values, leukocyte values, comorbid diseases, The cluster of differentiations 4 and 8 (CD4 and CD8), interleukin -2, interleukin -6, Tumor necrosis factor-alpha-beta levels will be recorded. Clinical results, changes in inflammatory and immune function levels, and side effects will be recorded. The patient's lung function and symptoms will be recorded after Mesenchymal Stem Cell transplantation. After treatment, lymphocyte, C-reactive protein, Tumor Necrosis alpha-beta levels , interleukin-6 levels will be recorded. Patients were divided into 3 groups: 1. group: Intubated without comorbidity (n:7) 2. group: Intubated with comorbidity (n:7) 3. group: No intubated (n:7) Dosage of Mesenchymal stem cells: 1. 1 million cell/kg iv--------------------------------------------------day 0 2. 1 million cell/kg iv -------------------------------------------------day 2 3. 1 million cell/kg iv -------------------------------------------------day 4

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: July 15, 2020
• Est. primary completion date: June 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• aged 18-90 male or female
• laboratory approve of RT-PCR (real-time reverse transcription polymerase chain reaction) with COVID-19 infection
• pneumonia assessed by chest radiography or computed tomography
• In accordance with any of the following: 1)Respiratory rate = 30 times / min 2) oxygen saturation = 93% 3) arterial pressure of oxygen/the fraction of inspired oxygen= 300mmHg, 4) pulmonary imaging of focus within 24-48 hours > 50% progression
• patients who remain unresponsive to medications administered according to Ministry of health guidelines
• Patients who receiving invasive or non-invasive mechanical ventilation therapy in intensive care

Exclusion Criteria:

• Pregnancy
• Any kind of cancer, severe liver disease
• Failure to provide informed consent or comply with test requirements
• Known allergy or hypersensitivity to MSCs

Related Conditions & MeSH terms

• Coronavirus Disease 2019 (COVID-19) Pneumonia
• Pneumonia

Intervention

Other:
• Mesenchymal stem cells
Intravenous infusion of Mesenchymal stem cells

Locations

Country	Name	City	State
Turkey	University of Health Sciences	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Kanuni Sultan Suleyman Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of clinical symptoms as respiratory distress or need for oxygen support	Recovery of patient from mechanical and oxygen support	3 months
Primary	Change of cytokine storm parameters	respiratory rates < 30 times /min	3 months
Primary	Change of pulmonary functions	Oxygen saturation > 93% and pulmonary imaging of focus within 24-48 hours > 50% progression	3 months
Primary	Change of clinical symptoms	arterial pressure of oxygen/the fraction of inspired oxygen>300mmHg	3 months